Vertex Pharmaceuticals — how they publish

10 posts · curated by ViralLoop

43 posts from @VertexPharma, Jan 2024 to Aug 2026: a typical post earns 17 likes and 2 replies. That is more than 72% of the 275 other S&P 500 companies we hold content for. About 1 in 5 of their posts announces something.

Vertex Pharmaceuticals@VertexPharma

#Breaking: Today we announced updated data for our investigational islet cell therapy for the treatment of #Type1Diabetes. Learn more: t.co

Opens with an observation

Vertex Pharmaceuticals@VertexPharma

We are pleased to share new data from our Phase 1/2 clinical trial for our investigational type 1 diabetes treatment at the 2024 @amdiabetesassn Scientific Sessions. Learn more: t.co

Opens with an observation

Vertex Pharmaceuticals@VertexPharma

#Breaking: The U.S. FDA has accepted the application and granted Priority Review for our fifth investigational CFTR modulator #CysticFibrosis. Learn more: t.co

Opens with an observation

Vertex Pharmaceuticals@VertexPharma

We are excited to share that data for our investigational stem cell-derived, fully differentiated islet cell therapy for #Type1Diabetes were published in @NEJM. Learn more: t.co

Opens with an observation

Vertex Pharmaceuticals@VertexPharma

#Breaking: The U.S. FDA has approved our newest treatment for cystic fibrosis. Learn more: t.co

Opens with an observation

Vertex Pharmaceuticals@VertexPharma

We are excited to share that the FDA has accepted and granted priority review to the New Drug Application (NDA) submission for our investigational acute pain medicine. Learn more: t.co

Opens with an observation

Vertex Pharmaceuticals@VertexPharma

#Breaking The U.S. FDA approves our treatment for #BetaThalassemia. We are thrilled to see this approval provide a new option to eligible patients who have been waiting. Learn more: t.co

Opens with an observation

Vertex Pharmaceuticals@VertexPharma

Today the European Commission approved our fifth cystic fibrosis (CF) medicine. This marks an important step towards our goal of treating all people with CF.

Opens with an announcement

Vertex Pharmaceuticals@VertexPharma

We are proud to announce that our acute pain medicine has been recognized as a 2025 Breakthroughs Innovation Celebration winner by @PremierHA, a leading healthcare improvement company. Learn more: t.co

Opens with an observation

Vertex Pharmaceuticals@VertexPharma

Today the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for the label expansion of our fourth cystic fibrosis (CF) medicine to include an expanded population with certain mutations. This marks an important step

Opens with an announcement